[go: up one dir, main page]

WO2007012671A3 - Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé - Google Patents

Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé Download PDF

Info

Publication number
WO2007012671A3
WO2007012671A3 PCT/EP2006/064798 EP2006064798W WO2007012671A3 WO 2007012671 A3 WO2007012671 A3 WO 2007012671A3 EP 2006064798 W EP2006064798 W EP 2006064798W WO 2007012671 A3 WO2007012671 A3 WO 2007012671A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxin
electrotransfer
antiserum
genetic immunization
obtainable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/064798
Other languages
English (en)
Other versions
WO2007012671A9 (fr
WO2007012671A2 (fr
Inventor
Daniel Scherman
Pascal Bigey
Capucine Trollet
Michel R Popoff
Yannick Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002617082A priority Critical patent/CA2617082A1/fr
Priority to US11/989,573 priority patent/US20100129371A1/en
Priority to EP06778059A priority patent/EP1906996A2/fr
Priority to JP2008523373A priority patent/JP2009502880A/ja
Publication of WO2007012671A2 publication Critical patent/WO2007012671A2/fr
Publication of WO2007012671A9 publication Critical patent/WO2007012671A9/fr
Publication of WO2007012671A3 publication Critical patent/WO2007012671A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention a pour objet un procédé d'obtention d'un antisérum dirigé contre une toxine protéique par administration chez un animal d'une solution comprenant une construction génétique codant un fragment immunogène de toxine, suivie de l'application d'un champ électrique dans la zone d'administration, et isolement du sérum. L'antisérum susceptible d'être obtenu par le procédé ainsi que l'utilisation de la solution pour la fabrication d'un médicament destiné à prévenir ou à traiter un effet toxique lié à l'absorption chez un mammifère d'une toxine, caractérisée en ce que ledit médicament est formulé en vue d'une administration par électrotransfert, sont également compris dans l'invention.
PCT/EP2006/064798 2005-07-28 2006-07-28 Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé Ceased WO2007012671A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002617082A CA2617082A1 (fr) 2005-07-28 2006-07-28 Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
US11/989,573 US20100129371A1 (en) 2005-07-28 2006-07-28 Method for genetic immunization by electrotransfer against a toxin and antiserum obtainable by said method
EP06778059A EP1906996A2 (fr) 2005-07-28 2006-07-28 Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé
JP2008523373A JP2009502880A (ja) 2005-07-28 2006-07-28 毒素に対する電気移動による遺伝子免疫法および前記方法によって得られる抗血清

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508065A FR2889066B1 (fr) 2005-07-28 2005-07-28 Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
FR0508065 2005-07-28

Publications (3)

Publication Number Publication Date
WO2007012671A2 WO2007012671A2 (fr) 2007-02-01
WO2007012671A9 WO2007012671A9 (fr) 2007-03-15
WO2007012671A3 true WO2007012671A3 (fr) 2007-04-26

Family

ID=36101879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064798 Ceased WO2007012671A2 (fr) 2005-07-28 2006-07-28 Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé

Country Status (6)

Country Link
US (1) US20100129371A1 (fr)
EP (1) EP1906996A2 (fr)
JP (1) JP2009502880A (fr)
CA (1) CA2617082A1 (fr)
FR (1) FR2889066B1 (fr)
WO (1) WO2007012671A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2011143557A2 (fr) 2010-05-14 2011-11-17 The Children's Hospital Of Philadelphia Ttc humanisé et procédés d'utilisation associés
CA2898303A1 (fr) 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Vaccin a base de neurotoxine botulinique mono ou multivalente utilisant la chaine lourde de serotypes de clostridium botulinum
CN111122455B (zh) * 2019-12-20 2022-10-25 华南协同创新研究院 一种食品真菌毒素结构的稳定性判定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001158A1 (fr) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
WO2000067700A2 (fr) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Vaccin de recombinaison contre la neurotoxine botulique
WO2003012117A1 (fr) * 2001-07-28 2003-02-13 The Secretary Of State For Defence Vaccin a adn

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832901A1 (fr) * 1996-09-18 1998-04-01 Roche Diagnostics GmbH Anticorps contre le virus hépatite G, leur utilisation diagnostique pour la détection de HGV, et comme agent thérapeutique
ES2371913T3 (es) * 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001158A1 (fr) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
WO2000067700A2 (fr) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Vaccin de recombinaison contre la neurotoxine botulique
WO2003012117A1 (fr) * 2001-07-28 2003-02-13 The Secretary Of State For Defence Vaccin a adn

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BACHY MONIQUE ET AL: "Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 13-14, 8 February 2001 (2001-02-08), pages 1688 - 1693, XP002183367, ISSN: 0264-410X *
BLOQUEL CAROLE ET AL: "Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications.", THE JOURNAL OF GENE MEDICINE. FEB 2004, vol. 6 Suppl 1, February 2004 (2004-02-01), pages S11 - S23, XP009064942, ISSN: 1099-498X *
DURIEUX ANNE-CÉCILE ET AL: "Kinetic of transgene expression after electrotransfer into skeletal muscle: importance of promoter origin/strength.", BIOCHIMICA ET BIOPHYSICA ACTA. 10 OCT 2005, vol. 1725, no. 3, 12 July 2005 (2005-07-12), pages 403 - 409, XP002376182, ISSN: 0006-3002 *
GARMORY HELEN S ET AL: "DNA vaccines for biodefence.", ADVANCED DRUG DELIVERY REVIEWS. 17 JUN 2005, vol. 57, no. 9, 17 June 2005 (2005-06-17), pages 1343 - 1361, XP004921415, ISSN: 0169-409X *
MCMAHON J M ET AL: "Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase -- increased expression with reduced muscle damage.", GENE THERAPY. AUG 2001, vol. 8, no. 16, August 2001 (2001-08-01), pages 1264 - 1270, XP009005905, ISSN: 0969-7128 *
MCMAHON JILLIAN M ET AL: "Electroporation for gene transfer to skeletal muscles: current status.", BIODRUGS : CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY. 2004, vol. 18, no. 3, 2004, pages 155 - 165, XP009064939, ISSN: 1173-8804 *
SHYU R-H ET AL: "DNA VACCINATION USING THE FRAGMENT C OF BOTULINUM NEUROTOXIN TYPE A PROVIDED PROTECTIVE IMMUNITY IN MICE", JOURNAL OF BIOMEDICAL SCIENCE, KARGER, BASEL, CH, vol. 7, no. 1, 2000, pages 51 - 57, XP009002343, ISSN: 1021-7770 *

Also Published As

Publication number Publication date
JP2009502880A (ja) 2009-01-29
FR2889066A1 (fr) 2007-02-02
CA2617082A1 (fr) 2007-02-01
US20100129371A1 (en) 2010-05-27
EP1906996A2 (fr) 2008-04-09
FR2889066B1 (fr) 2007-11-09
WO2007012671A9 (fr) 2007-03-15
WO2007012671A2 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2008036341A3 (fr) Compositions et procédés concernant des anticorps de récepteur du glucagon
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
JO2576B1 (en) Antibodies
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2009100331A3 (fr) Compositions, méthodes et kits de stimulation de la réponse immunitaire à une maladie respiratoire
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
SG10201903166PA (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MY147217A (en) Antibody molecules having specificity for human il-06
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
WO2008027739A3 (fr) Anticorps vis-à-vis de ntb-a
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
WO2010025321A3 (fr) Procédé de traitement de patients souffrant de sclérose en plaques avec des anticorps anti-il2r
WO2006076651A3 (fr) Procede de traitement
TW200507840A (en) Method of treating multiple myeloma
WO2007103876A3 (fr) Agent thérapeutique anticancéreux
WO2007012671A3 (fr) Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé
WO2010101301A9 (fr) Traitement prophylaxique et thérapeutique de la dégénérescence maculaire et de la rétinopathie à l'aide d'un prdx
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose
WO2006002195A3 (fr) Procede de complexation d'une proteine au moyen d'un systeme disperse et proteines ainsi obtenues
WO2004009028A3 (fr) Methodes et composition permettant de traiter et de prevenir l'infection grippale et les symptomes associes
WO2007007160A3 (fr) Anticorps anti-madcam servant a traiter la fievre
WO2006138589A3 (fr) Ligands de recepteur opioide
WO2004049917A3 (fr) Procedes de therapie et de diagnostic utilisant le ciblage de cellules d'expression de ly-9

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008523373

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2617082

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006778059

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06778059

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006778059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11989573

Country of ref document: US